Cigna Plans To Reiterate Its Full-year Outlook

Cigna Corporation (CI) plans to reaffirm its full-year 2021 consolidated adjusted revenues of at least $166 billion, the company said in a filing with the SEC.

The company intends to back its guidance during its meetings with investors and analysts, planned over the next several weeks.

Cigna also expects to reiterate its full-year guidance for adjusted income from operations of at least $7 billion or $20.20 per share and projected weighted average shares outstanding in the range of 346 million to 348 million.

This outlook includes about 1.25 per share in net impact of Covid-19 as well as impact of future share repurchases and expected 2021 dividends.

Analysts polled by Thomson Reuters expect the company to report earnings of $20.43 per share on revenue of $166.46 billion for the full-year. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Flavor maker McCormick & Co., Inc. is recalling certain McCormick and Frank's brand seasoning products citing possible salmonella risk, the U.S. Food and Drug Administration said. The recall involves McCormick Perfect Pinch Italian Seasoning, McCormick Culinary Italian Seasoning and Frank's RedHot Buffalo Ranch Seasoning. Drug major Pfizer Inc. raised Wednesday its outlook for fiscal 2021 earnings and revenues following strong second quarter results that exceeded market estimates. According to the company, the upward revision in full-year outlook, for the second quarter in a row, reflects its updated expectations for contributions to 2021 performance from both BNT162b2, the Pfizer-BioNTech SE COVID-19 vaccine. While reporting financial results for the second quarter on Wednesday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) reaffirmed its adjusted earnings and revenue growth guidance for the full-year 2021. For fiscal 2021, the company now projects earnings in a range of $3.18 to $3.38 per share,...
Follow RTT